Mediator affair takes up EMA resources, anti-fraud investigation could soak more
This article was originally published in SRA
Executive Summary
The European Medicines Agency has had to allocate "considerable" unplanned resources to dealing with the Mediator drug affair, according to its half-year report1. The agency is likely to dedicate even more to dealing with the fallout as an anti-fraud investigation into the agency in connection with the scandal is underway. Meanwhile, other planned work, including implementing new pharmacovigilance legislation, has been delayed, according to the report.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.